SUNPHARMA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Fda Classifies Sun Pharma Halol Facility As 'official Action Indicated'
Sun Pharma Discontinues Manufacturing Of Vecuronium Bromide Injection 20 MG, Says FDA
Health Rounds: Clopidogrel better than aspirin for preventing heart attacks and strokes
This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here
By Nancy Lapid
Sept 3 (Reuters) - The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
RECYCLED PACEMAKERS IMPROVE ACCESS IN LOW-INCOME NATIONS
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(To receive the full newsletter in your inbox for free sign up here)
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here
By Nancy Lapid
Sept 3 (Reuters) - The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
RECYCLED PACEMAKERS IMPROVE ACCESS IN LOW-INCOME NATIONS
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(To receive the full newsletter in your inbox for free sign up here)
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
Health Rounds: Clopidogrel better than aspirin for preventing heart attacks and strokes
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here
By Nancy Lapid
Sept 2 (Reuters) - Hello Health Rounds readers! Today we highlight two studies presented at the European Society of Cardiology meeting in Madrid, one that compared widely used blood thinners for preventing serious heart problems, and one that tested the safety of reusing cardiac pacemakers.
Clopidogrel tops aspirin for routine use in heart patients
The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
Recycled pacemakers improve access in low-income nations
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here
By Nancy Lapid
Sept 2 (Reuters) - Hello Health Rounds readers! Today we highlight two studies presented at the European Society of Cardiology meeting in Madrid, one that compared widely used blood thinners for preventing serious heart problems, and one that tested the safety of reusing cardiac pacemakers.
Clopidogrel tops aspirin for routine use in heart patients
The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
Recycled pacemakers improve access in low-income nations
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
Does a common heart attack pill help everyone? Studies disagree
In two large studies of heart attack survivors, beta-blocker drugs benefited those with mildly impaired heart function
Contradictory trial results seen in patients without heart dysfunction
More data on beta-blockers in patients with normally functioning hearts expected in November
By Nancy Lapid
Aug 30 (Reuters) - A decades-old pill remains helpful for heart attack patients even with modern treatments that can prevent lasting damage to heart muscle, two large trials have shown.
Still unclear is whether all patients, or only some, benefit from so-called beta-blocker drugs, which are typically prescribed to everyone after a heart attack.
Two sharply contradictory reports were presented on Saturday at a large cardiology meeting in Madrid and published in The New England Journal of Medicine.
“It is not unusual for trials to yield different results,” said Dr. Borja Ibanez of Centro Nacional de Investigaciones Cardiovasculares Carlos III in Madrid, who led one of the trials.
“Somewhat uncommon is to see two trials with apparently divergent findings presented on the same day.”
Most important, Ibanez said, is the finding both teams agree on, which is that beta-blockers reduce the combined risk of another heart attack, heart failure, or death in patients without heart failure but with mildly impaired heart function.
The question is whether the pills are beneficial or useless for those with normally functioning hearts, who account for about 80% of patients after a first heart attack.
Beta-blocker manufacturers include Mylan, Novartis NOVN.S, Pfizer PFE.N, Abbott, Teva Pharmaceutical Industries TEVA.TA, Amneal Pharmaceuticals AMRX.O, Sun Pharmaceutical Industries SUN.NS, Lupin, ANI Pharmaceuticals ANIP.O, and Eagle Pharmaceuticals EGRX.PK.
The drugs work by inhibiting the hormones epinephrine and norepinephrine, thereby lowering heart rate and blood pressure, decreasing the workload on the heart and reducing its oxygen demand.
Both new trials involved heart attack survivors whose hearts were still contracting normally, that is, the left ventricle was pumping out at least 40% of its blood with each beat. Both trials followed patients for roughly 3.5 years.
Among 5,574 volunteers in the BETAMI–DANBLOCK study from Norway and Denmark, the drugs showed a clear benefit. Patients randomly assigned to receive beta-blockers had a 15% lower risk of death or major adverse cardiovascular event, particularly a repeat heart attack, compared to patients not taking these pills, investigators found.
But among the 8,438 participants in the REBOOT trial conducted in Italy and Spain, beta-blockers had no effect on the incidence of death from any cause, a repeat heart attack, or hospitalization for heart failure, according to a separate report.
Some of the difference may be due to the fact that patients didn't all receive the same beta-blockers, and the Scandinavian patients might have been more prone to adverse events because they were slightly older than patients in Spain and Italy and more of them had mild heart dysfunction, said Dr. Dan Atar of the University of Oslo, who led one of the trials.
Among female participants in REBOOT, those taking beta-blockers - particularly those with good heart function receiving higher doses – had more adverse outcomes than women not taking the drugs, researchers reported in the European Heart Journal.
In REBOOT, researchers did see a lower rate of new heart attacks, heart failure, or death with beta-blocker use by patients with mildly reduced heart function, as indicated by a left ventricular “ejection fraction” between 40% and 49%.
The effect in this subgroup was confirmed in an analysis of data pooled from REBOOT, BETAMI–DANBLOCK, and a Japanese trial, according to a report published in The Lancet.
The message for cardiologists, Ibanez said, is “We can now state with confidence that beta-blockers are beneficial” in patients with mildly impaired heart function, and “there remains reasonable uncertainty about their benefit” in patients with normally functioning hearts.
Atar said an analysis looking specifically at beta-blocker use by patients with normal heart function will be presented at a U.S. cardiology meeting in November.
(Reporting by Nancy Lapid; editing by Caroline Humer and Diane Craft)
(([email protected];))
In two large studies of heart attack survivors, beta-blocker drugs benefited those with mildly impaired heart function
Contradictory trial results seen in patients without heart dysfunction
More data on beta-blockers in patients with normally functioning hearts expected in November
By Nancy Lapid
Aug 30 (Reuters) - A decades-old pill remains helpful for heart attack patients even with modern treatments that can prevent lasting damage to heart muscle, two large trials have shown.
Still unclear is whether all patients, or only some, benefit from so-called beta-blocker drugs, which are typically prescribed to everyone after a heart attack.
Two sharply contradictory reports were presented on Saturday at a large cardiology meeting in Madrid and published in The New England Journal of Medicine.
“It is not unusual for trials to yield different results,” said Dr. Borja Ibanez of Centro Nacional de Investigaciones Cardiovasculares Carlos III in Madrid, who led one of the trials.
“Somewhat uncommon is to see two trials with apparently divergent findings presented on the same day.”
Most important, Ibanez said, is the finding both teams agree on, which is that beta-blockers reduce the combined risk of another heart attack, heart failure, or death in patients without heart failure but with mildly impaired heart function.
The question is whether the pills are beneficial or useless for those with normally functioning hearts, who account for about 80% of patients after a first heart attack.
Beta-blocker manufacturers include Mylan, Novartis NOVN.S, Pfizer PFE.N, Abbott, Teva Pharmaceutical Industries TEVA.TA, Amneal Pharmaceuticals AMRX.O, Sun Pharmaceutical Industries SUN.NS, Lupin, ANI Pharmaceuticals ANIP.O, and Eagle Pharmaceuticals EGRX.PK.
The drugs work by inhibiting the hormones epinephrine and norepinephrine, thereby lowering heart rate and blood pressure, decreasing the workload on the heart and reducing its oxygen demand.
Both new trials involved heart attack survivors whose hearts were still contracting normally, that is, the left ventricle was pumping out at least 40% of its blood with each beat. Both trials followed patients for roughly 3.5 years.
Among 5,574 volunteers in the BETAMI–DANBLOCK study from Norway and Denmark, the drugs showed a clear benefit. Patients randomly assigned to receive beta-blockers had a 15% lower risk of death or major adverse cardiovascular event, particularly a repeat heart attack, compared to patients not taking these pills, investigators found.
But among the 8,438 participants in the REBOOT trial conducted in Italy and Spain, beta-blockers had no effect on the incidence of death from any cause, a repeat heart attack, or hospitalization for heart failure, according to a separate report.
Some of the difference may be due to the fact that patients didn't all receive the same beta-blockers, and the Scandinavian patients might have been more prone to adverse events because they were slightly older than patients in Spain and Italy and more of them had mild heart dysfunction, said Dr. Dan Atar of the University of Oslo, who led one of the trials.
Among female participants in REBOOT, those taking beta-blockers - particularly those with good heart function receiving higher doses – had more adverse outcomes than women not taking the drugs, researchers reported in the European Heart Journal.
In REBOOT, researchers did see a lower rate of new heart attacks, heart failure, or death with beta-blocker use by patients with mildly reduced heart function, as indicated by a left ventricular “ejection fraction” between 40% and 49%.
The effect in this subgroup was confirmed in an analysis of data pooled from REBOOT, BETAMI–DANBLOCK, and a Japanese trial, according to a report published in The Lancet.
The message for cardiologists, Ibanez said, is “We can now state with confidence that beta-blockers are beneficial” in patients with mildly impaired heart function, and “there remains reasonable uncertainty about their benefit” in patients with normally functioning hearts.
Atar said an analysis looking specifically at beta-blocker use by patients with normal heart function will be presented at a U.S. cardiology meeting in November.
(Reporting by Nancy Lapid; editing by Caroline Humer and Diane Craft)
(([email protected];))
India's Sun Pharma reports higher adjusted quarterly profit on strong domestic demand
Adds details paragraph 3 onwards
July 31 (Reuters) - Sun Pharmaceutical Industries SUN.NS, India's largest drugmaker by revenue, reported a higher adjusted profit on Thursday, aided by strong domestic sales.
The Mumbai-based firm's consolidated profit before tax and exceptional items rose 16.6% to 39.91 billion rupees ($455.6 million) in the quarter ended June 30.
The drugmaker reported a one-time charge of 8.18 billion rupees in the first quarter related to the impairment of certain assets and the settlement of a legal dispute.
Accounting for the charge, profit fell nearly 20% on-year.
Total revenue grew 9.5% to 138.51 billion rupees, beating analysts' estimates of 136.51 billion rupees. The rise in revenue was supported by a 14% increase in sales in India, Sun Pharma's largest revenue-generating region.
The firm has been focusing on strengthening its portfolio of innovative drugs in dermatology, oncology and obesity therapy areas as it targets mid-to-high single-digit percentage revenue growth in the current fiscal year.
Sales from its high-margin global innovative segment, which includes drugs used to treat rare and complex chronic conditions such as hair loss and psoriasis, rose 16.9% and accounted for 19.3% of the total.
Its U.S. sales climbed 4% to 40.45 billion rupees. While India's generic drugmakers derive a significant share of revenue from the United States, pricing pressures due to stiff competition continue to weigh on profit margins.
($1 = 87.6000 Indian rupees)
(Reporting by Rishika Sadam in Hyderabad and Kashish Tandon in Bengaluru; Editing by Sonia Cheema)
(([email protected];))
Adds details paragraph 3 onwards
July 31 (Reuters) - Sun Pharmaceutical Industries SUN.NS, India's largest drugmaker by revenue, reported a higher adjusted profit on Thursday, aided by strong domestic sales.
The Mumbai-based firm's consolidated profit before tax and exceptional items rose 16.6% to 39.91 billion rupees ($455.6 million) in the quarter ended June 30.
The drugmaker reported a one-time charge of 8.18 billion rupees in the first quarter related to the impairment of certain assets and the settlement of a legal dispute.
Accounting for the charge, profit fell nearly 20% on-year.
Total revenue grew 9.5% to 138.51 billion rupees, beating analysts' estimates of 136.51 billion rupees. The rise in revenue was supported by a 14% increase in sales in India, Sun Pharma's largest revenue-generating region.
The firm has been focusing on strengthening its portfolio of innovative drugs in dermatology, oncology and obesity therapy areas as it targets mid-to-high single-digit percentage revenue growth in the current fiscal year.
Sales from its high-margin global innovative segment, which includes drugs used to treat rare and complex chronic conditions such as hair loss and psoriasis, rose 16.9% and accounted for 19.3% of the total.
Its U.S. sales climbed 4% to 40.45 billion rupees. While India's generic drugmakers derive a significant share of revenue from the United States, pricing pressures due to stiff competition continue to weigh on profit margins.
($1 = 87.6000 Indian rupees)
(Reporting by Rishika Sadam in Hyderabad and Kashish Tandon in Bengaluru; Editing by Sonia Cheema)
(([email protected];))
Sun Pharmaceutical Industries Says Ilumya Studies Meet Primary Endpoint In Psoriatic Arthritis
July 21 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMACEUTICAL INDUSTRIES LTD - ILUMYA STUDIES MEET PRIMARY ENDPOINT IN PSORIATIC ARTHRITIS
SUN PHARMACEUTICAL INDUSTRIES LTD - ILUMYA SHOWS SIGNIFICANT ACR20 IMPROVEMENTS AT WEEK 24
SUN PHARMACEUTICAL INDUSTRIES LTD - RESULTS SUPPORT POTENTIAL US SUBMISSION FOR ILUMYA IN PSORIATIC ARTHRITIS
Source text: ID:nBSE56mL6Z
Further company coverage: SUN.NS
(([email protected];))
July 21 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMACEUTICAL INDUSTRIES LTD - ILUMYA STUDIES MEET PRIMARY ENDPOINT IN PSORIATIC ARTHRITIS
SUN PHARMACEUTICAL INDUSTRIES LTD - ILUMYA SHOWS SIGNIFICANT ACR20 IMPROVEMENTS AT WEEK 24
SUN PHARMACEUTICAL INDUSTRIES LTD - RESULTS SUPPORT POTENTIAL US SUBMISSION FOR ILUMYA IN PSORIATIC ARTHRITIS
Source text: ID:nBSE56mL6Z
Further company coverage: SUN.NS
(([email protected];))
Sun Pharma Says Unit Incorporated In China
July 17 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
UNIT INCORPORATED IN CHINA
Source text: ID:nBSEc9SWhn
Further company coverage: SUN.NS
(([email protected];;))
July 17 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
UNIT INCORPORATED IN CHINA
Source text: ID:nBSEc9SWhn
Further company coverage: SUN.NS
(([email protected];;))
India's Sun Pharma launches anti-baldness drug Leqselvi in US
July 14 (Reuters) - India's top drugmaker by revenue, Sun Pharma SUN.NS, on Monday launched its anti-baldness drug Leqselvi in the U.S., following settlement of a patent dispute with Incyte Corp INCY.O.
(Reporting by Manvi Pant; Editing by Mrigank Dhaniwala)
(([email protected]; +918447554364;))
July 14 (Reuters) - India's top drugmaker by revenue, Sun Pharma SUN.NS, on Monday launched its anti-baldness drug Leqselvi in the U.S., following settlement of a patent dispute with Incyte Corp INCY.O.
(Reporting by Manvi Pant; Editing by Mrigank Dhaniwala)
(([email protected]; +918447554364;))
Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market
Updates paragraph 1, adds details on Novo Nordisk and Eli Lilly
June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's LLY.N blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo Nordisk's NOVOb.CO recently launched Wegovy.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker launched its blockbuster weight-loss drug Wegovy in India on June 24, three months after Eli Lilly began marketing its rival product Mounjaro.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.
GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
ELI LILLY
Lilly started selling Mounjaro in India in late March for diabetes and obesity, beating rival Novo to the market. The doses available were 2.5 mg and 5 mg vials.
On Thursday, Mounjaro KwikPen - for once-weekly use - was approved by the Central Drugs Standard Control Organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Maju Samuel)
(([email protected];))
Updates paragraph 1, adds details on Novo Nordisk and Eli Lilly
June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's LLY.N blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo Nordisk's NOVOb.CO recently launched Wegovy.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker launched its blockbuster weight-loss drug Wegovy in India on June 24, three months after Eli Lilly began marketing its rival product Mounjaro.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.
GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
ELI LILLY
Lilly started selling Mounjaro in India in late March for diabetes and obesity, beating rival Novo to the market. The doses available were 2.5 mg and 5 mg vials.
On Thursday, Mounjaro KwikPen - for once-weekly use - was approved by the Central Drugs Standard Control Organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Maju Samuel)
(([email protected];))
India's Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
May 22 (Reuters) - Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
($1 = 85.9500 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)
(([email protected]; 8800437922;))
May 22 (Reuters) - Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
($1 = 85.9500 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)
(([email protected]; 8800437922;))
Sun Pharmaceutical Industries Says FDA Approves Blu-U For Actinic Keratosis
May 16 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
FDA APPROVES SUN PHARMA'S NEXT GEN BLU-U FOR ACTINIC KERATOSIS
Source text: ID:nBSE7vk0mN
Further company coverage: SUN.NS
(([email protected];))
May 16 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
FDA APPROVES SUN PHARMA'S NEXT GEN BLU-U FOR ACTINIC KERATOSIS
Source text: ID:nBSE7vk0mN
Further company coverage: SUN.NS
(([email protected];))
Indian pharma stocks drop as Trump to sign executive order to cut prices of medicines
May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.
Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.
Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.
Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.
The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.
Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.
The U.S. imports nearly a third of Indian pharma products sold overseas.
India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)
(([email protected]; 8800437922;))
May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.
Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.
Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.
Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.
The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.
Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.
The U.S. imports nearly a third of Indian pharma products sold overseas.
India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)
(([email protected]; 8800437922;))
Sun Pharma Says Co, Moebius Medical Announce Dual Publications On MM-II's Phase 2B Clinical Trial
April 24 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMA - CO, MOEBIUS MEDICAL ANNOUNCE DUAL PUBLICATIONS ON MM-II'S PHASE 2B CLINICAL TRIAL
SUN PHARMACEUTICAL INDUSTRIES LTD - PHASE 2B TRIAL SHOWS MM-II PROVIDES PAIN RELIEF FOR 26 WEEKS
Source text: ID:nBSEb3mspZ
Further company coverage: SUN.NS
(([email protected];))
April 24 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMA - CO, MOEBIUS MEDICAL ANNOUNCE DUAL PUBLICATIONS ON MM-II'S PHASE 2B CLINICAL TRIAL
SUN PHARMACEUTICAL INDUSTRIES LTD - PHASE 2B TRIAL SHOWS MM-II PROVIDES PAIN RELIEF FOR 26 WEEKS
Source text: ID:nBSEb3mspZ
Further company coverage: SUN.NS
(([email protected];))
Sun Pharmaceutical Industries Says U.S. Court Of Appeals Vacates Preliminary Injunction On Leqselvi
April 10 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMACEUTICAL INDUSTRIES LTD - U.S. COURT OF APPEALS VACATES PRELIMINARY INJUNCTION ON LEQSELVI
SUN PHARMACEUTICAL INDUSTRIES - LITIGATION WITH INCYTE CONTINUES, PRELIMINARY INJUNCTION LIFTED
SUN PHARMA - NO LONGER UNDER COURT ORDER THAT DELAYS OR RESTRICTS CO FROM LAUNCHING LEQSELVI
SUN PHARMA - COMPANY WILL DISCLOSE LEQSELVI LAUNCH PLANS IN DUE COURSE OF TIME
Source text: ID:nNSE8JBxwV
Further company coverage: SUN.NS
(([email protected];))
April 10 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMACEUTICAL INDUSTRIES LTD - U.S. COURT OF APPEALS VACATES PRELIMINARY INJUNCTION ON LEQSELVI
SUN PHARMACEUTICAL INDUSTRIES - LITIGATION WITH INCYTE CONTINUES, PRELIMINARY INJUNCTION LIFTED
SUN PHARMA - NO LONGER UNDER COURT ORDER THAT DELAYS OR RESTRICTS CO FROM LAUNCHING LEQSELVI
SUN PHARMA - COMPANY WILL DISCLOSE LEQSELVI LAUNCH PLANS IN DUE COURSE OF TIME
Source text: ID:nNSE8JBxwV
Further company coverage: SUN.NS
(([email protected];))
UPDATE 5-Global pharma shares plunge as Trump doubles down on tariff threat
US drugmakers' shares drop 3% to 6% premarket
European, Indian healthcare stocks drag down broader indexes
Trump aims to shift pharma manufacturing to US, but analysts doubtful
Adds analyst comments in paragraphs 11-12, updates share moves throughout
By Manas Mishra and Ananta Agarwal
April 9 (Reuters) - Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and as his country-specific reciprocal tariffs took effect, leading to more pain in global markets.
Pharmaceutical imports were initially exempt from Trump's first set of reciprocal tariffs last week — but his administration has since indicated that levies on the sector, which in the past has been excluded from such actions, are coming.
The U.S. president has said the tariffs will incentivize drug companies to move operations to the United States. However, analysts and companies have raised concerns about the difficulty in setting up manufacturing in the country.
Shares of major U.S. drugmakers Amgen AMGN.O, AbbVie ABBV.N, Pfizer PFE.N, Merck MRK.N and Eli Lilly LLY.N fell between 3% and 6% in premarket trading.
In Europe, a basket of healthcare stocks .SXDP fell 5% to its lowest since October 2022, leading losses among sectoral indexes on the region-wide STOXX 600 .STOXX, which was down 3.3% at 1013 GMT. The index was heading for its biggest one-day drop since March 2020.
Trump had also threatened the duties on Friday after his first set of "reciprocal" tariffs exempted pharma products. Trump has not said when and by how much he plans to raise levies on pharma imports.
"While the details are scant, we are strongly opposed to tariffs on any pharmaceuticals — these will likely do little to shift manufacturing back to the U.S.," said BMO Capital Markets analyst Evan Seigerman.
"Given the complexity of the pharma supply chain, we do not expect the industry to make any major changes. These current tariffs are being pursued under emergency powers, which at worse will last until the end of the current administration and could end sooner with an act of Congress."
Seigerman also pointed to concerns over recent layoffs at the U.S. Food and Drug Administration, saying the worries were now compounded by the "real talk" of pharma tariffs.
ADDITIONAL COSTS, LONG WAIT FOR PRODUCTION
Europe and the U.S. have interconnected supply chains for medicines. The United States depends on medicines partly produced in Europe that bring in hundreds of billions of dollars in revenue.
Bernstein analyst Courtney Breen wrote in a note that her worst-case scenario assumes tariffs could be steep, leading to about $53 billion in additional costs paid for pharmaceutical imports.
If companies did choose to bring new manufacturing to the United States, Breen expects additional spend of $2 billion for each new "green field" site and a five-year runway to production.
EU medical and pharmaceutical product exports to the U.S. totaled about 90 billion euros ($97 billion) in 2023, according to latest Eurostat data.
Shares of AstraZeneca AZN.L, GSK GSK.L, Roche ROG.S, Sanofi SASY.PA and Novartis NOVN.S fell between 5% and 6.5% in Europe. Meanwhile, Indian pharmaceutical stocks .NIPHARM closed nearly 2% lower, dragging down the benchmark Nifty 50 .NSEI by 0.6%.
IPCA Laboratories IPCA.NS, Glenmark Pharma GLEN.NS and Biocon BION.NS were the top losers by percentage on the pharma index in Mumbai, ending the trading session between 4% and 5.5% lower.
India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. The United States accounts for a third of India's overall pharma exports.
European pharma companies hit by looming tariff threat https://reut.rs/3Efihqg
BREAKINGVIEWS-Big Pharma has partial immunity from Trump tariffs nL5N3QM18T
(Reporting by Kashish Tandon, Ananta Agarwal and Manas Mishra in Bengaluru and Anna Pruchnicka in Gdansk; Editing by Savio D'Souza, Mrigank Dhaniwala and Shounak Dasgupta)
US drugmakers' shares drop 3% to 6% premarket
European, Indian healthcare stocks drag down broader indexes
Trump aims to shift pharma manufacturing to US, but analysts doubtful
Adds analyst comments in paragraphs 11-12, updates share moves throughout
By Manas Mishra and Ananta Agarwal
April 9 (Reuters) - Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and as his country-specific reciprocal tariffs took effect, leading to more pain in global markets.
Pharmaceutical imports were initially exempt from Trump's first set of reciprocal tariffs last week — but his administration has since indicated that levies on the sector, which in the past has been excluded from such actions, are coming.
The U.S. president has said the tariffs will incentivize drug companies to move operations to the United States. However, analysts and companies have raised concerns about the difficulty in setting up manufacturing in the country.
Shares of major U.S. drugmakers Amgen AMGN.O, AbbVie ABBV.N, Pfizer PFE.N, Merck MRK.N and Eli Lilly LLY.N fell between 3% and 6% in premarket trading.
In Europe, a basket of healthcare stocks .SXDP fell 5% to its lowest since October 2022, leading losses among sectoral indexes on the region-wide STOXX 600 .STOXX, which was down 3.3% at 1013 GMT. The index was heading for its biggest one-day drop since March 2020.
Trump had also threatened the duties on Friday after his first set of "reciprocal" tariffs exempted pharma products. Trump has not said when and by how much he plans to raise levies on pharma imports.
"While the details are scant, we are strongly opposed to tariffs on any pharmaceuticals — these will likely do little to shift manufacturing back to the U.S.," said BMO Capital Markets analyst Evan Seigerman.
"Given the complexity of the pharma supply chain, we do not expect the industry to make any major changes. These current tariffs are being pursued under emergency powers, which at worse will last until the end of the current administration and could end sooner with an act of Congress."
Seigerman also pointed to concerns over recent layoffs at the U.S. Food and Drug Administration, saying the worries were now compounded by the "real talk" of pharma tariffs.
ADDITIONAL COSTS, LONG WAIT FOR PRODUCTION
Europe and the U.S. have interconnected supply chains for medicines. The United States depends on medicines partly produced in Europe that bring in hundreds of billions of dollars in revenue.
Bernstein analyst Courtney Breen wrote in a note that her worst-case scenario assumes tariffs could be steep, leading to about $53 billion in additional costs paid for pharmaceutical imports.
If companies did choose to bring new manufacturing to the United States, Breen expects additional spend of $2 billion for each new "green field" site and a five-year runway to production.
EU medical and pharmaceutical product exports to the U.S. totaled about 90 billion euros ($97 billion) in 2023, according to latest Eurostat data.
Shares of AstraZeneca AZN.L, GSK GSK.L, Roche ROG.S, Sanofi SASY.PA and Novartis NOVN.S fell between 5% and 6.5% in Europe. Meanwhile, Indian pharmaceutical stocks .NIPHARM closed nearly 2% lower, dragging down the benchmark Nifty 50 .NSEI by 0.6%.
IPCA Laboratories IPCA.NS, Glenmark Pharma GLEN.NS and Biocon BION.NS were the top losers by percentage on the pharma index in Mumbai, ending the trading session between 4% and 5.5% lower.
India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. The United States accounts for a third of India's overall pharma exports.
European pharma companies hit by looming tariff threat https://reut.rs/3Efihqg
BREAKINGVIEWS-Big Pharma has partial immunity from Trump tariffs nL5N3QM18T
(Reporting by Kashish Tandon, Ananta Agarwal and Manas Mishra in Bengaluru and Anna Pruchnicka in Gdansk; Editing by Savio D'Souza, Mrigank Dhaniwala and Shounak Dasgupta)
Novo preparing for early launch of weight-loss drug Wegovy in India
By Rishika Sadam
HYDERABAD, April 7 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly LLY.N in the populous nation, two sources familiar with the plans told Reuters.
Novo, which had earlier planned for a 2026 launch of the drug, is now looking to begin selling Wegovy in India "this year, probably in the next few months," sources told Reuters on condition of anonymity as they were not authorized to talk to the media.
"Novo's also assessing the stock situation to handle the demand in India. They want to avoid any shortage issues," one of the sources said.
The company's accelerated plan follows U.S. rival Eli Lilly's launch of its diabetes and obesity drug Mounjaro in India last month.
Reuters reported earlier that Novo's India team had been pushing the global headquarters for an early Wegovy launch.
Novo and Lilly have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers to among the world's most valuable companies.
The competing drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
Semaglutide, the active ingredient in Novo's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving way for generic drugmakers to produce cheaper versions of the drugs.
Local drugmakers such as Sun Pharma SUN.NS, Cipla CIPL.NS and Dr Reddy's REDY.NS have been racing to build up supplies with an eye on a share of a global market analysts have estimated could be worth $150 billion annually in the next decade.
Novo declined to comment on Monday, but previously said Wegovy has been approved in India. It did not have a confirmed date for the medicine's India launch at the time.
"Novo also thinks that its brand names Ozempic, Wegovy have better penetration in the market, which would give them an edge," the other source said.
Still, Novo would need to offer the drug at a competitive price to Lilly's once-weekly Mounjaro injection, which costs about $50 for a 5 milligram vial, and $40 for a 2.5 mg vial, the lowest doses.
(Reporting by Rishika Sadam in Hyderabad and Maggie Fick in London; Editing by Bill Berkrot)
(([email protected];))
By Rishika Sadam
HYDERABAD, April 7 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly LLY.N in the populous nation, two sources familiar with the plans told Reuters.
Novo, which had earlier planned for a 2026 launch of the drug, is now looking to begin selling Wegovy in India "this year, probably in the next few months," sources told Reuters on condition of anonymity as they were not authorized to talk to the media.
"Novo's also assessing the stock situation to handle the demand in India. They want to avoid any shortage issues," one of the sources said.
The company's accelerated plan follows U.S. rival Eli Lilly's launch of its diabetes and obesity drug Mounjaro in India last month.
Reuters reported earlier that Novo's India team had been pushing the global headquarters for an early Wegovy launch.
Novo and Lilly have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers to among the world's most valuable companies.
The competing drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
Semaglutide, the active ingredient in Novo's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving way for generic drugmakers to produce cheaper versions of the drugs.
Local drugmakers such as Sun Pharma SUN.NS, Cipla CIPL.NS and Dr Reddy's REDY.NS have been racing to build up supplies with an eye on a share of a global market analysts have estimated could be worth $150 billion annually in the next decade.
Novo declined to comment on Monday, but previously said Wegovy has been approved in India. It did not have a confirmed date for the medicine's India launch at the time.
"Novo also thinks that its brand names Ozempic, Wegovy have better penetration in the market, which would give them an edge," the other source said.
Still, Novo would need to offer the drug at a competitive price to Lilly's once-weekly Mounjaro injection, which costs about $50 for a 5 milligram vial, and $40 for a 2.5 mg vial, the lowest doses.
(Reporting by Rishika Sadam in Hyderabad and Maggie Fick in London; Editing by Bill Berkrot)
(([email protected];))
Trump's latest tariff threat ends brief reprieve for Indian pharma stocks
By Kashish Tandon
April 4 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 4.4% on Friday, wiping out gains from the previous session, after U.S. President Donald Trump threatened steep tariffs on the sector.
"Pharma (tariffs) is going to be starting to come in, I think, at a level that you haven't really seen before," Trump told reporters aboard Air Force One.
"That will be announced in the near future, and is under review right now," Trump said.
The index was among the top sectoral losers by percentage on the benchmark Nifty 50 .NSEI, which was down about 1.2% at 11:25 a.m. IST.
All 20 constituents of the pharma index were trading in the red, with Sun Pharma SUN.NS, Dr Reddy's REDY.NS and Cipla CIPL.NS being the biggest drags.
Lupin LUPN.NS, Aurobindo Pharma ARBN. and Ipca Laboratories IPCA.NS fell about 6.5% each, and were the top losers by percentage.
Trump imposed a 10% tariff on most U.S. imports earlier this week, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland.
Pharma stocks were a rare bright spot on Thursday as global drugmakers gained on relief that their products remained temporarily shielded from the tariffs.
However, executives and analysts had warned it was premature to celebrate as levies were still likely to come.
"If these tariffs are introduced, the manufacturers will have no choice but to pass on the impact to consumers," said Vishal Manchanda, an analyst at Systematix Institutional Equities.
Indian drugmakers have been on a 'wait and watch' mode and also raised concerns on the difficulty in setting up manufacturing in the U.S., a move that would increase their costs.
Trump in his Wednesday address had predicted pharma companies would come "roaring back" to the U.S, and warned that "they got a big tax to pay" if they don't.
(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)
(([email protected]; 8800437922;))
By Kashish Tandon
April 4 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 4.4% on Friday, wiping out gains from the previous session, after U.S. President Donald Trump threatened steep tariffs on the sector.
"Pharma (tariffs) is going to be starting to come in, I think, at a level that you haven't really seen before," Trump told reporters aboard Air Force One.
"That will be announced in the near future, and is under review right now," Trump said.
The index was among the top sectoral losers by percentage on the benchmark Nifty 50 .NSEI, which was down about 1.2% at 11:25 a.m. IST.
All 20 constituents of the pharma index were trading in the red, with Sun Pharma SUN.NS, Dr Reddy's REDY.NS and Cipla CIPL.NS being the biggest drags.
Lupin LUPN.NS, Aurobindo Pharma ARBN. and Ipca Laboratories IPCA.NS fell about 6.5% each, and were the top losers by percentage.
Trump imposed a 10% tariff on most U.S. imports earlier this week, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland.
Pharma stocks were a rare bright spot on Thursday as global drugmakers gained on relief that their products remained temporarily shielded from the tariffs.
However, executives and analysts had warned it was premature to celebrate as levies were still likely to come.
"If these tariffs are introduced, the manufacturers will have no choice but to pass on the impact to consumers," said Vishal Manchanda, an analyst at Systematix Institutional Equities.
Indian drugmakers have been on a 'wait and watch' mode and also raised concerns on the difficulty in setting up manufacturing in the U.S., a move that would increase their costs.
Trump in his Wednesday address had predicted pharma companies would come "roaring back" to the U.S, and warned that "they got a big tax to pay" if they don't.
(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)
(([email protected]; 8800437922;))
Indian pharma stocks defy market slump on US tariffs exemption
April 3 (Reuters) - Shares of Indian drugmakers surged 4% on Thursday, in contrast to the drop in the broader stock market, after U.S. President Donald Trump's administration exempted pharmaceutical products from the list of imports hit by reciprocal tariffs.
The pharma sub-index .NIPHARM was the only one among the 13 major sectors that was trading higher. The benchmark Nifty 50 .NSEI was down 0.74%.
Trump imposed a 26% reciprocal tariff on Indian imports as part of his wider plan to impose a 10% baseline tariff on all imports from April 5, but the duties do not apply to certain goods, including pharmaceuticals.
The U.S. imports nearly a third of Indian pharma products sold overseas. India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
On the day, Dr Reddy's REDY.NS climbed 6% and was the top gainer on the benchmark Nifty 50 index. Gland Pharma GLAD.NS surged 12% and was the top gainer among pharma stocks.
Cipla CIPL.NS and Sun Pharma SUN.NS rose 4% each.
(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)
(([email protected]; 8800437922;))
April 3 (Reuters) - Shares of Indian drugmakers surged 4% on Thursday, in contrast to the drop in the broader stock market, after U.S. President Donald Trump's administration exempted pharmaceutical products from the list of imports hit by reciprocal tariffs.
The pharma sub-index .NIPHARM was the only one among the 13 major sectors that was trading higher. The benchmark Nifty 50 .NSEI was down 0.74%.
Trump imposed a 26% reciprocal tariff on Indian imports as part of his wider plan to impose a 10% baseline tariff on all imports from April 5, but the duties do not apply to certain goods, including pharmaceuticals.
The U.S. imports nearly a third of Indian pharma products sold overseas. India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
On the day, Dr Reddy's REDY.NS climbed 6% and was the top gainer on the benchmark Nifty 50 index. Gland Pharma GLAD.NS surged 12% and was the top gainer among pharma stocks.
Cipla CIPL.NS and Sun Pharma SUN.NS rose 4% each.
(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)
(([email protected]; 8800437922;))
UPDATE 5-Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Lilly beats Novo Nordisk to launch weight-loss drug in India
Mounjaro's 5 mg vial priced at around $50, 2.5 mg at about $40
Drug's pricing may limit accessibility in India, analyst says
Novo's Wegovy already approved in India
Updates March 20 story with Novo Nordisk comment on Wegovy launch timing in paragraph 11
By Rishika Sadam
HYDERABAD, March 21 (Reuters) - Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.
U.S.-based Lilly LLY.N and Danish Novo Nordisk NOVOb.CO have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.
Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively. Its highest dose is 15 mg.
A patient in India may have to spend about $200 a month when taking a weekly dose of 5 mg, subject to doctor's prescription.
Mounjaro carries a list price of $1,086.37 for each monthly fill in the U.S., but the amount patients pay largely depends on their insurance plan. Lilly also offers 5 mg, 7.5 mg and 10 mg vials of Zepbound, with prices around $499 for a month's supply if customers pay directly in cash without any third-party entities.
Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes and weight loss. It is sold as Zepbound for obesity in the U.S.
Lilly, however, said that the pricing in different geographies cannot be compared given significant variation in healthcare systems, economies and reimbursement policies in each country.
"(Mounjaro) launch is ahead of Novo Nordisk and the first mover advantage should help ... but pricing seems high (for the Indian market). At the highest dose, a patient will have to spend close to 700,000 rupees (around $8,100) per annum," Vishal Manchanda, analyst at Systematix Institutional Equities said.
Novo's weight-loss drug, Wegovy, can cost non-insured U.S. patients more than $1,000 a month.
Novo's India team has been pushing the global leadership to launch Wegovy as early as 2025 in the country as opposed to the company's target of a 2026 launch.
The drugmaker told Reuters that Wegovy has already been approved in India, but said it did not have a confirmed date for the medicine's launch there.
The company's shares were down 0.6% at 1145 GMT, underperforming the broader European market .STOXX. Shares of U.S.-based Lilly rose as much as 2.07% to $854.39 on Thursday.
Novo's stock has fallen over 12% so far this year, while Lilly's has jumped 8%.
Novo is not the only competition Lilly will have to confront in India. Local drugmakers such as Sun Pharma SUN.NS, Cipla CIPL.NS, Dr. Reddy's REDY.NS and Lupin LUPN.NS have been racing to make generic versions of these drugs to grab a share of the global market estimated to be worth $150 billion in the next decade.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
"The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India," said President and General Manager Winselow Tucker at Lilly India.
Obesity and diabetes rates in India, a country of more than 1.4 billion people, have been steadily climbing. The number of adults with diabetes is set to increase to over 124 million by 2045 from 74.2 million in 2021, according to International Diabetes Federation.
Meanwhile, a government survey conducted between 2019 and 2021 showed that 24% of women and nearly 23% of men between the ages of 15 and 49 were either overweight or obese, up from 20.6% of women and 19% of men in 2015-2016.
Wegovy and Novo's diabetes drug, Ozempic — which has the same main ingredient — and Mounjaro, belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
($1 = 86.3425 Indian rupees)
FACTBOX- Lilly's weight-loss drug launch in India to energize rivals eyeing mega market https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-weight-loss-drug-launch-india-energize-rivals-eyeing-mega-market-2025-03-20/
Countries where Eli Lilly's Mounjaro is launched or approved https://reut.rs/4hFAf33
(Reporting by Rishika Sadam in Hyderabad, Maggie Fick in London and Bhanvi Satija in Bengaluru; Additional reporting by Manvi Pant in Bengaluru; Editing by Janane Venkatraman, Alan Barona and Tomasz Janowski)
Lilly beats Novo Nordisk to launch weight-loss drug in India
Mounjaro's 5 mg vial priced at around $50, 2.5 mg at about $40
Drug's pricing may limit accessibility in India, analyst says
Novo's Wegovy already approved in India
Updates March 20 story with Novo Nordisk comment on Wegovy launch timing in paragraph 11
By Rishika Sadam
HYDERABAD, March 21 (Reuters) - Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.
U.S.-based Lilly LLY.N and Danish Novo Nordisk NOVOb.CO have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.
Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively. Its highest dose is 15 mg.
A patient in India may have to spend about $200 a month when taking a weekly dose of 5 mg, subject to doctor's prescription.
Mounjaro carries a list price of $1,086.37 for each monthly fill in the U.S., but the amount patients pay largely depends on their insurance plan. Lilly also offers 5 mg, 7.5 mg and 10 mg vials of Zepbound, with prices around $499 for a month's supply if customers pay directly in cash without any third-party entities.
Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes and weight loss. It is sold as Zepbound for obesity in the U.S.
Lilly, however, said that the pricing in different geographies cannot be compared given significant variation in healthcare systems, economies and reimbursement policies in each country.
"(Mounjaro) launch is ahead of Novo Nordisk and the first mover advantage should help ... but pricing seems high (for the Indian market). At the highest dose, a patient will have to spend close to 700,000 rupees (around $8,100) per annum," Vishal Manchanda, analyst at Systematix Institutional Equities said.
Novo's weight-loss drug, Wegovy, can cost non-insured U.S. patients more than $1,000 a month.
Novo's India team has been pushing the global leadership to launch Wegovy as early as 2025 in the country as opposed to the company's target of a 2026 launch.
The drugmaker told Reuters that Wegovy has already been approved in India, but said it did not have a confirmed date for the medicine's launch there.
The company's shares were down 0.6% at 1145 GMT, underperforming the broader European market .STOXX. Shares of U.S.-based Lilly rose as much as 2.07% to $854.39 on Thursday.
Novo's stock has fallen over 12% so far this year, while Lilly's has jumped 8%.
Novo is not the only competition Lilly will have to confront in India. Local drugmakers such as Sun Pharma SUN.NS, Cipla CIPL.NS, Dr. Reddy's REDY.NS and Lupin LUPN.NS have been racing to make generic versions of these drugs to grab a share of the global market estimated to be worth $150 billion in the next decade.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
"The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India," said President and General Manager Winselow Tucker at Lilly India.
Obesity and diabetes rates in India, a country of more than 1.4 billion people, have been steadily climbing. The number of adults with diabetes is set to increase to over 124 million by 2045 from 74.2 million in 2021, according to International Diabetes Federation.
Meanwhile, a government survey conducted between 2019 and 2021 showed that 24% of women and nearly 23% of men between the ages of 15 and 49 were either overweight or obese, up from 20.6% of women and 19% of men in 2015-2016.
Wegovy and Novo's diabetes drug, Ozempic — which has the same main ingredient — and Mounjaro, belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
($1 = 86.3425 Indian rupees)
FACTBOX- Lilly's weight-loss drug launch in India to energize rivals eyeing mega market https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-weight-loss-drug-launch-india-energize-rivals-eyeing-mega-market-2025-03-20/
Countries where Eli Lilly's Mounjaro is launched or approved https://reut.rs/4hFAf33
(Reporting by Rishika Sadam in Hyderabad, Maggie Fick in London and Bhanvi Satija in Bengaluru; Additional reporting by Manvi Pant in Bengaluru; Editing by Janane Venkatraman, Alan Barona and Tomasz Janowski)
FACTBOX-Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
(([email protected];))
March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
(([email protected];))
India's Sun Pharma to acquire Checkpoint Therapeutics
March 10 (Reuters) - India's Sun Pharmaceutical Industries SUN.NS said on Monday that it will acquire Checkpoint Therapeutics CKPT.O, a U.S.-based immunotherapy and targeted oncology company, in a deal valued at up to $355 million.
(Reporting by Aleef Jahan in Bengaluru; Editing by Sherry Jacob-Phillips)
March 10 (Reuters) - India's Sun Pharmaceutical Industries SUN.NS said on Monday that it will acquire Checkpoint Therapeutics CKPT.O, a U.S.-based immunotherapy and targeted oncology company, in a deal valued at up to $355 million.
(Reporting by Aleef Jahan in Bengaluru; Editing by Sherry Jacob-Phillips)
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
Repeats March 1 story with no change to text
By Rishika Sadam
MUMBAI, March 1 (Reuters) - India's largest drugmaker by revenue Sun Pharmaceutical SUN.NS is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said on Friday.
The company is among many Indian drugmakers looking to grab a slice of the growing weight-loss drug market, which is expected to reach $150 billion globally by the end of the decade.
Sun Pharma's push into this category comes after companies such as Novo Nordisk NOVOb.CO and Eli Lilly LLY.N saw skyrocketing demand for their weight-loss drugs Wegovy and Zepbound, which boosted the drugmakers' valuations.
Sun Pharma's novel investigational drug, also known as Utreglutide (GL0034), belongs to a drug class called GLP-1 receptor agonists, which suppress appetite by mimicking gut hormones and have also been found to have medical benefits for conditions beyond type 2 diabetes and weight loss.
The active ingredients in Wegovy and Zepbound also belong to the same class of drugs.
Sun Pharma, which expects to conduct mid-stage trials for the drug this year, earlier said it demonstrated clinically meaningful weight loss and significant metabolic improvements in the first phase of trials.
"The findings highlight GL0034's potential as a therapeutic option for individuals with obesity, providing not only weight loss but also improvements in key cardiometabolic biomarkers," it said last year.
The company will focus on launching it in India as well as global markets, a source with knowledge of the matter said on Friday.
Sun Pharma said in August it would consider a partnership or licensing the product in large markets such as the U.S. and Europe for commercialization.
Generic drugmakers such as Dr Reddy's REDY.NS, Cipla CIPL.NS and Lupin LUPN.NS are also developing their own generic versions of these drugs, the launch of which is subject to patent expiry of active ingredients in original drugs.
(Reporting by Rishika Sadam in Mumbai; Editing by Shounak Dasgupta)
Repeats March 1 story with no change to text
By Rishika Sadam
MUMBAI, March 1 (Reuters) - India's largest drugmaker by revenue Sun Pharmaceutical SUN.NS is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said on Friday.
The company is among many Indian drugmakers looking to grab a slice of the growing weight-loss drug market, which is expected to reach $150 billion globally by the end of the decade.
Sun Pharma's push into this category comes after companies such as Novo Nordisk NOVOb.CO and Eli Lilly LLY.N saw skyrocketing demand for their weight-loss drugs Wegovy and Zepbound, which boosted the drugmakers' valuations.
Sun Pharma's novel investigational drug, also known as Utreglutide (GL0034), belongs to a drug class called GLP-1 receptor agonists, which suppress appetite by mimicking gut hormones and have also been found to have medical benefits for conditions beyond type 2 diabetes and weight loss.
The active ingredients in Wegovy and Zepbound also belong to the same class of drugs.
Sun Pharma, which expects to conduct mid-stage trials for the drug this year, earlier said it demonstrated clinically meaningful weight loss and significant metabolic improvements in the first phase of trials.
"The findings highlight GL0034's potential as a therapeutic option for individuals with obesity, providing not only weight loss but also improvements in key cardiometabolic biomarkers," it said last year.
The company will focus on launching it in India as well as global markets, a source with knowledge of the matter said on Friday.
Sun Pharma said in August it would consider a partnership or licensing the product in large markets such as the U.S. and Europe for commercialization.
Generic drugmakers such as Dr Reddy's REDY.NS, Cipla CIPL.NS and Lupin LUPN.NS are also developing their own generic versions of these drugs, the launch of which is subject to patent expiry of active ingredients in original drugs.
(Reporting by Rishika Sadam in Mumbai; Editing by Shounak Dasgupta)
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
By Rishika Sadam
MUMBAI, March 1 (Reuters) - India's largest drugmaker by revenue Sun Pharmaceutical SUN.NS is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said on Friday.
The company is among many Indian drugmakers looking to grab a slice of the growing weight-loss drug market, which is expected to reach $150 billion globally by the end of the decade.
Sun Pharma's push into this category comes after companies such as Novo Nordisk NOVOb.CO and Eli Lilly LLY.N saw skyrocketing demand for their weight-loss drugs Wegovy and Zepbound, which boosted the drugmakers' valuations.
Sun Pharma's novel investigational drug, also known as Utreglutide (GL0034), belongs to a drug class called GLP-1 receptor agonists, which suppress appetite by mimicking gut hormones and have also been found to have medical benefits for conditions beyond type 2 diabetes and weight loss.
The active ingredients in Wegovy and Zepbound also belong to the same class of drugs.
Sun Pharma, which expects to conduct mid-stage trials for the drug this year, earlier said it demonstrated clinically meaningful weight loss and significant metabolic improvements in the first phase of trials.
"The findings highlight GL0034's potential as a therapeutic option for individuals with obesity, providing not only weight loss but also improvements in key cardiometabolic biomarkers," it said last year.
The company will focus on launching it in India as well as global markets, a source with knowledge of the matter said on Friday.
Sun Pharma said in August it would consider a partnership or licensing the product in large markets such as the U.S. and Europe for commercialization.
Generic drugmakers such as Dr Reddy's REDY.NS, Cipla CIPL.NS and Lupin LUPN.NS are also developing their own generic versions of these drugs, the launch of which is subject to patent expiry of active ingredients in original drugs.
(Reporting by Rishika Sadam in Mumbai; Editing by Shounak Dasgupta)
By Rishika Sadam
MUMBAI, March 1 (Reuters) - India's largest drugmaker by revenue Sun Pharmaceutical SUN.NS is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said on Friday.
The company is among many Indian drugmakers looking to grab a slice of the growing weight-loss drug market, which is expected to reach $150 billion globally by the end of the decade.
Sun Pharma's push into this category comes after companies such as Novo Nordisk NOVOb.CO and Eli Lilly LLY.N saw skyrocketing demand for their weight-loss drugs Wegovy and Zepbound, which boosted the drugmakers' valuations.
Sun Pharma's novel investigational drug, also known as Utreglutide (GL0034), belongs to a drug class called GLP-1 receptor agonists, which suppress appetite by mimicking gut hormones and have also been found to have medical benefits for conditions beyond type 2 diabetes and weight loss.
The active ingredients in Wegovy and Zepbound also belong to the same class of drugs.
Sun Pharma, which expects to conduct mid-stage trials for the drug this year, earlier said it demonstrated clinically meaningful weight loss and significant metabolic improvements in the first phase of trials.
"The findings highlight GL0034's potential as a therapeutic option for individuals with obesity, providing not only weight loss but also improvements in key cardiometabolic biomarkers," it said last year.
The company will focus on launching it in India as well as global markets, a source with knowledge of the matter said on Friday.
Sun Pharma said in August it would consider a partnership or licensing the product in large markets such as the U.S. and Europe for commercialization.
Generic drugmakers such as Dr Reddy's REDY.NS, Cipla CIPL.NS and Lupin LUPN.NS are also developing their own generic versions of these drugs, the launch of which is subject to patent expiry of active ingredients in original drugs.
(Reporting by Rishika Sadam in Mumbai; Editing by Shounak Dasgupta)
Top Indian drugmakers bank on bilateral talks for relief from planned US tariffs (February 20)
Corrects paragraph 10 in February 20 story to say generic drugs overall, not just those supplied by Indian drugmakers, resulted in $408 billion in savings for the U.S. healthcare system
By Rishika Sadam
HYDERABAD Feb 20 (Reuters) - Indian drugmakers are hoping that bilateral discussions between the country and the United States will help them steer clear of President Donald Trump's plan to levy at least 25% tariffs on pharmaceutical imports, a trade association said.
India, which calls itself the 'pharmacy of the world', makes cheaper generic versions of complex innovative drugs in its massive factory clusters and exports them to over 200 countries, of which the U.S. is its biggest market, government data shows.
"This (tariff) matter will be discussed through bilateral engagements between the two countries and further steps will be determined accordingly," Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), said in a statement on Wednesday.
"We are confident that continued dialogue among stakeholders will help address the subject."
The IPA represents some of India's biggest drugmakers, including Sun Pharmaceutical SUN.NS, Dr Reddy's REDY.NS, Cipla CIPL.NS and Zydus Lifesciences ZYDU.NS, and the local units of U.S. firms such as Abbott ABT.N.
Earlier this week, Sun Pharma Managing Director Dilip Shanghvi told local media that the tariffs, if imposed, will be passed on to consumers.
In fiscal 2024, exports to the U.S. were worth $8.7 billion, or about 31% of total pharma exports, data from government-backed trade body Pharmexcil showed. Trump's tariff threat sent shares of Indian drugmakers sliding on Wednesday.
"The government will certainly have discussion about the changing situations and try to bring the best possible solution," Pharmexcil Director General Raja Bhanu told Reuters on Thursday.
"Our USP is quality, affordability," Bhanu said, adding that it makes India's exports highly competitive.
According to research firm IQVIA, nearly half of all prescriptions for generic medicines in the United States in 2022 were supplied by Indian drugmakers. Overall generic drugs saved the U.S. health system about $408 billion.
In an interview with Fox News which aired on Tuesday, Trump said he told Prime Minister Narendra Modi that the U.S. will follow reciprocal tariff method and charge the same as what India does.
Separately, on Wednesday, he said the tariffs could be announced 'next month or sooner.'
India imposes about 10% tax on pharma imports from the U.S. while paying almost nil import tariff for its pharmaceutical products in the U.S., according to industry experts.
"This (tariff) move is going to be inflationary to the U.S. as they don't have the requisite manufacturing infrastructure in-house to replace the scale of supply that India does," said Vishal Manchanda, an analyst at Systematix Institutional Equities.
(Reporting by Rishika Sadam; Editing by Savio D'Souza and Eileen Soreng)
(([email protected];))
Corrects paragraph 10 in February 20 story to say generic drugs overall, not just those supplied by Indian drugmakers, resulted in $408 billion in savings for the U.S. healthcare system
By Rishika Sadam
HYDERABAD Feb 20 (Reuters) - Indian drugmakers are hoping that bilateral discussions between the country and the United States will help them steer clear of President Donald Trump's plan to levy at least 25% tariffs on pharmaceutical imports, a trade association said.
India, which calls itself the 'pharmacy of the world', makes cheaper generic versions of complex innovative drugs in its massive factory clusters and exports them to over 200 countries, of which the U.S. is its biggest market, government data shows.
"This (tariff) matter will be discussed through bilateral engagements between the two countries and further steps will be determined accordingly," Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), said in a statement on Wednesday.
"We are confident that continued dialogue among stakeholders will help address the subject."
The IPA represents some of India's biggest drugmakers, including Sun Pharmaceutical SUN.NS, Dr Reddy's REDY.NS, Cipla CIPL.NS and Zydus Lifesciences ZYDU.NS, and the local units of U.S. firms such as Abbott ABT.N.
Earlier this week, Sun Pharma Managing Director Dilip Shanghvi told local media that the tariffs, if imposed, will be passed on to consumers.
In fiscal 2024, exports to the U.S. were worth $8.7 billion, or about 31% of total pharma exports, data from government-backed trade body Pharmexcil showed. Trump's tariff threat sent shares of Indian drugmakers sliding on Wednesday.
"The government will certainly have discussion about the changing situations and try to bring the best possible solution," Pharmexcil Director General Raja Bhanu told Reuters on Thursday.
"Our USP is quality, affordability," Bhanu said, adding that it makes India's exports highly competitive.
According to research firm IQVIA, nearly half of all prescriptions for generic medicines in the United States in 2022 were supplied by Indian drugmakers. Overall generic drugs saved the U.S. health system about $408 billion.
In an interview with Fox News which aired on Tuesday, Trump said he told Prime Minister Narendra Modi that the U.S. will follow reciprocal tariff method and charge the same as what India does.
Separately, on Wednesday, he said the tariffs could be announced 'next month or sooner.'
India imposes about 10% tax on pharma imports from the U.S. while paying almost nil import tariff for its pharmaceutical products in the U.S., according to industry experts.
"This (tariff) move is going to be inflationary to the U.S. as they don't have the requisite manufacturing infrastructure in-house to replace the scale of supply that India does," said Vishal Manchanda, an analyst at Systematix Institutional Equities.
(Reporting by Rishika Sadam; Editing by Savio D'Souza and Eileen Soreng)
(([email protected];))
Duopharma Biotech Says Writ Of Summons Served By Sun Pharmaceutical Industries
Feb 20 (Reuters) - Duopharma Biotech DUOP.KL:
WRIT OF SUMMONS SERVED ON UNIT BY SUN PHARMACEUTICAL INDUSTRIES
Further company coverage: DUOP.KL
(([email protected];))
Feb 20 (Reuters) - Duopharma Biotech DUOP.KL:
WRIT OF SUMMONS SERVED ON UNIT BY SUN PHARMACEUTICAL INDUSTRIES
Further company coverage: DUOP.KL
(([email protected];))
Indian pharma stocks drop on Trump's tariff plans
Feb 19 (Reuters) - Shares of Indian pharmaceutical companies .NIPHARM slid 2.2% on Wednesday after U.S. President Donald Trump said he intends to impose tariffs in the range of 25% on pharma imports.
Sun Pharma SUN.NS and Dr Reddy's REDY.NS fell 2% and 3.4%, respectively, while Aurobindo Pharma ARBN.NS tumbled 6%.
(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)
(([email protected]; 8800437922;))
Feb 19 (Reuters) - Shares of Indian pharmaceutical companies .NIPHARM slid 2.2% on Wednesday after U.S. President Donald Trump said he intends to impose tariffs in the range of 25% on pharma imports.
Sun Pharma SUN.NS and Dr Reddy's REDY.NS fell 2% and 3.4%, respectively, while Aurobindo Pharma ARBN.NS tumbled 6%.
(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)
(([email protected]; 8800437922;))
Sun Pharma MD Tells ET NOW Possible US Tariffs To Have No Major Impact On Indian Pharma Industry
Feb 17 (Reuters) - Sun Pharma MD To ET NOW:
NO MAJOR IMPACT OF POSSIBLE US TARIFFS ON INDIAN PHARMA INDUSTRY
ANY IMPACT FROM US TARIFFS WILL BE MINIMAL
MOST OF THE US TARIFFS, IF IMPOSED, WILL BE PASSED ON TO CONSUMERS
Further company coverage: SUN.NS
(([email protected];))
Feb 17 (Reuters) - Sun Pharma MD To ET NOW:
NO MAJOR IMPACT OF POSSIBLE US TARIFFS ON INDIAN PHARMA INDUSTRY
ANY IMPACT FROM US TARIFFS WILL BE MINIMAL
MOST OF THE US TARIFFS, IF IMPOSED, WILL BE PASSED ON TO CONSUMERS
Further company coverage: SUN.NS
(([email protected];))
Sun Pharma Says Philogen Completes Patient Enrollment Of The Phase III Fibrosarc Trial In Soft Tissue Sarcoma
Feb 4 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMA - PHILOGEN COMPLETES PATIENT ENROLLMENT OF THE PHASE III FIBROSARC TRIAL IN SOFT TISSUE SARCOMA
Source text: [ID:]
Further company coverage: SUN.NS
(([email protected];))
Feb 4 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMA - PHILOGEN COMPLETES PATIENT ENROLLMENT OF THE PHASE III FIBROSARC TRIAL IN SOFT TISSUE SARCOMA
Source text: [ID:]
Further company coverage: SUN.NS
(([email protected];))
Top Indian drugmaker Sun Pharma's Q3 profit beats estimates on strong local sales
Adds analyst comment in paragraph 5
By Kashish Tandon and Rishika Sadam
HYDERABAD/BENGALURU Jan 31 (Reuters) - Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided by strong sales in the domestic market.
The Mumbai-based firm's consolidated net profit rose 15% to 29.03 billion rupees ($335.3 million) in the third quarter, beating analysts' average estimate of 28.81 billion rupees, according to data compiled by LSEG.
Sales in India, Sun Pharma's largest revenue-generating region, rose 14% to 43 billion rupees, or about 31% of total sales. That was bigger than the 11% increase in the previous quarter.
Its high-margin global specialty pharmaceutical segment, which includes medicines for conditions such as alopecia and psoriasis, reported a 17.5% jump in sales to $370 million, or 21% of total sales.
"Increasing contribution from global specialty drugs is a key positive for Sun Pharma and will continue to boost margins in near term, said Shrikant Akolkar, an analyst at Nuvama Institutional Equities.
Overall, the company's revenue rose 10.5% to 136.75 billion rupees, surpassing analysts' estimates of 134.22 billion rupees.
That was despite U.S. sales increasing just 0.7%.
Most of India's generic drugmakers derive a significant share of revenue from the United States, where lower drug prices due to stiff competition have been weighing on profit margins.
Among its rivals, Dr Reddy's REDY.NS missed profit estimates for the quarter, while Cipla CIPL.NS beat expectations. However, both the generic drugmakers saw muted growth in their key North American market.
($1 = 86.5860 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Savio D'Souza)
(([email protected];))
Adds analyst comment in paragraph 5
By Kashish Tandon and Rishika Sadam
HYDERABAD/BENGALURU Jan 31 (Reuters) - Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided by strong sales in the domestic market.
The Mumbai-based firm's consolidated net profit rose 15% to 29.03 billion rupees ($335.3 million) in the third quarter, beating analysts' average estimate of 28.81 billion rupees, according to data compiled by LSEG.
Sales in India, Sun Pharma's largest revenue-generating region, rose 14% to 43 billion rupees, or about 31% of total sales. That was bigger than the 11% increase in the previous quarter.
Its high-margin global specialty pharmaceutical segment, which includes medicines for conditions such as alopecia and psoriasis, reported a 17.5% jump in sales to $370 million, or 21% of total sales.
"Increasing contribution from global specialty drugs is a key positive for Sun Pharma and will continue to boost margins in near term, said Shrikant Akolkar, an analyst at Nuvama Institutional Equities.
Overall, the company's revenue rose 10.5% to 136.75 billion rupees, surpassing analysts' estimates of 134.22 billion rupees.
That was despite U.S. sales increasing just 0.7%.
Most of India's generic drugmakers derive a significant share of revenue from the United States, where lower drug prices due to stiff competition have been weighing on profit margins.
Among its rivals, Dr Reddy's REDY.NS missed profit estimates for the quarter, while Cipla CIPL.NS beat expectations. However, both the generic drugmakers saw muted growth in their key North American market.
($1 = 86.5860 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Savio D'Souza)
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Large Cap Ideas
See similar 'Large' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Sun Pharma Inds. do?
Sun Pharmaceutical Industries Limited is a leading specialty generic pharmaceutical company in India, offering a wide range of high-quality and affordable products globally.
Who are the competitors of Sun Pharma Inds.?
Sun Pharma Inds. major competitors are Cipla, Torrent Pharma, Dr. Reddy's Lab, Mankind Pharma, Zydus Lifesciences, Lupin, Alkem Laboratories. Market Cap of Sun Pharma Inds. is ₹3,97,342 Crs. While the median market cap of its peers are ₹1,09,835 Crs.
Is Sun Pharma Inds. financially stable compared to its competitors?
Sun Pharma Inds. seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Sun Pharma Inds. pay decent dividends?
The company seems to pay a good stable dividend. Sun Pharma Inds. latest dividend payout ratio is 35.13% and 3yr average dividend payout ratio is 33.84%
How has Sun Pharma Inds. allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Sun Pharma Inds. balance sheet?
Balance sheet of Sun Pharma Inds. is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Sun Pharma Inds. improving?
The profit is oscillating. The profit of Sun Pharma Inds. is ₹10,411 Crs for TTM, ₹10,929 Crs for Mar 2025 and ₹9,576 Crs for Mar 2024.
Is the debt of Sun Pharma Inds. increasing or decreasing?
The net debt of Sun Pharma Inds. is decreasing. Latest net debt of Sun Pharma Inds. is -₹20,721.2 Crs as of Mar-25. This is less than Mar-24 when it was -₹18,171.43 Crs.
Is Sun Pharma Inds. stock expensive?
Sun Pharma Inds. is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Sun Pharma Inds. is 38.31, while 3 year average PE is 42.36. Also latest EV/EBITDA of Sun Pharma Inds. is 25.32 while 3yr average is 23.74.
Has the share price of Sun Pharma Inds. grown faster than its competition?
Sun Pharma Inds. has given lower returns compared to its competitors. Sun Pharma Inds. has grown at ~19.84% over the last 2yrs while peers have grown at a median rate of 24.81%
Is the promoter bullish about Sun Pharma Inds.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Sun Pharma Inds. is 54.48% and last quarter promoter holding is 54.48%.
Are mutual funds buying/selling Sun Pharma Inds.?
The mutual fund holding of Sun Pharma Inds. is increasing. The current mutual fund holding in Sun Pharma Inds. is 12.63% while previous quarter holding is 12.21%.